Veracyte (VCYT) Tops Q2 EPS by 2c, Amends Agreement with Sanofi's Genzyme
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Veracyte (VCYT) PT, Estimates Bumped at Piper Jaffray Despite Q2 Rev Miss
August 14, 2014 6:57 AM EDTPiper Jaffray analyst William Quirk reiterated an Overweight rating while bumping estimates and his price target on Veracyte, Inc (NASDAQ: VCYT) following Q2 results and the related after hours sell-off on the revenue miss.
Quirk comments, "Veracyte reported a 71.2% yoy revenue increase... More
